All In Biotech

NDA 021996 · Bausch and Lomb

Children'S Alaway

Ketotifen Fumarate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Apr 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Dec 1, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

20 Phase 3, 3 recruiting

FAERS reports

2,730

727 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2006 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetter
2 products under this application
  • CHILDREN'S ALAWAY · KETOTIFEN FUMARATE EQ 0.025% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
  • ALAWAY · KETOTIFEN FUMARATE EQ 0.025% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketotifen" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation489
  • drug ineffective410
  • eye pain204
  • pruritus158
  • treatment failure149
  • ocular hyperaemia147
  • urticaria126
  • eye pruritus123
  • headache120
  • fatigue118
  • nausea113
  • condition aggravated112

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20059
200610
200721
200873
200994
201011
201198
2012124
2013113
201423
201582
2016156
2017227
2018150
2019250
2020226
2021183
2022149
2023170
2024163
2025207
2026186

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 302 on PubMed

Sponsor: Bausch and Lomb · Also marketed as Alaway

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.